Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection
AbstractHIV-1 virus-like particles (VLPs) are promising vaccine candidates against HIV-1 infection. They are capable of preserving the native conformation of HIV-1 antigens and priming CD4+ and CD8+ T cell responses efficiently via cross presentation by both major histocompatibility complex (MHC) class I and II molecules. Progress has been achieved in the preclinical research of HIV-1 VLPs as prophylactic vaccines that induce broadly neutralizing antibodies and potent T cell responses. Moreover, the progress in HIV-1 dendritic cells (DC)-based immunotherapy provides us with a new vision for HIV-1 vaccine development. In this review, we describe updates from the past 5 years on the development of HIV-1 VLPs as a vaccine candidate and on the combined use of HIV particles with HIV-1 DC-based immunotherapy as efficient prophylactic and therapeutic vaccination strategies. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Zhao, C.; Ao, Z.; Yao, X. Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines 2016, 4, 2.
Zhao C, Ao Z, Yao X. Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines. 2016; 4(1):2.Chicago/Turabian Style
Zhao, Chongbo; Ao, Zhujun; Yao, Xiaojian. 2016. "Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection." Vaccines 4, no. 1: 2.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.